Aptinyx’s NYX-2925 Draws Skepticism As It Fails Another Trial

 
• By Alaric DeArment
  
Aptinyx said its Phase IIb trial of NYX-2925 in diabetic peripheral neuropathy did not meet its primary endpoint • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D